Loading...
•
Dec 31, 2019
Novocure Q4 2019 Earnings Report
Reported a revenue increase and a second quarter of positive net income.
Key Takeaways
Novocure reported a strong fourth quarter and full year 2019, with net revenues of $99.2 million for the quarter, representing a 42% increase compared to Q4 2018. The company achieved a net income of $4.3 million, a significant improvement from the net loss of $15.6 million in the same period of the previous year. Novocure ended the year with $326.1 million in cash, cash equivalents, and short-term investments.
Net revenues reached $99.2 million, a 42% increase compared to Q4 2018.
Achieved second quarter of positive net income with $0.04 earnings per share.
Active patients totaled 2,909 at the end of the period, representing 22% growth year-over-year.
Advanced clinical programs with four phase 3 pivotal clinical trials ongoing.
Revenue by Geographic Location
Forward Guidance
Novocure anticipates several clinical milestones, including interim analyses and data releases from ongoing phase 3 pivotal trials. The company is focused on advancing its proprietary cancer therapy platform and improving patient outcomes.
Positive Outlook
- Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (H2 2020)
- Data from phase 2 pilot HEPANOVA trial in advanced liver cancer (2021)
- Data from phase 3 pivotal METIS trial in brain metastases (2021)
- Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2021)
- Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022)
Challenges Ahead
- Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2022)
- Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2022)
- Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2024)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...